Introduction: Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that can progress to cirrhosis and hepatocellular carcinoma. Diagnosis of NASH requires liver biopsy and is defined as presence of hepatic steatosis and inflammation with or without fibrosis. Although NASH is the most common cause of liver disease in the west world and among the top three indications for liver transplantation, there are no universally accepted pharmacological therapies and advances have been slow. Expert commentary: As NASH is classified as a medical condition of an unmet therapeutic need, it has gained an accelerated access pathway for drug approval based on surrogate endpoints. It is therefore expected that within the next five years, there will be at least one approved agent for the pharmacological treatment of pre-cirrhotic NASH.
contributing to the rising prevalence of NAFLD [7] . NAFLD is projected to become the main indication for liver transplantation in the next 10 years [2, 3, 8] . Based on the histological features, NAFLD is differentiated in simple steatosis (NAFL) and nonalcoholic steatohepatitis (NASH) [2, 3] , which is characterized by lobular inflammation, ballooning and higher risk of progression to cirrhosis [9] . Although there is rigorous scientific interest in approaching novel therapeutic pathways to treat NASH, the gold standard remains lifestyle modification with a combination of weight loss and exercise [10, 11] . During the last decades, a variety of different agents, which target specific pathophysiologic mechanisms, have been studied in controlled trials in the treatment of NASH. A better understanding of NAFLD pathogenesis will not only help clarify how the disease progresses but may also result in the discovery of new treatment strategies. Potential therapeutic targets and approaches include the use of insulin sensitizers, antioxidants/anti-inflammatory and anti-fibrotic agents. This review focuses on therapeutic approaches that have already been tested in patients with NASH, with a brief mention on promising future agents that are already at least in phase II trials. 
Management principles
NAFL is considered a benign condition and is not associated with increased liver-related morbidity hence no liver-specific treatment is required. The presence of coexisting conditions like diabetes mellitus, dyslipidaemia and obesity should be investigated and managed [2, 3] . Conversely, patients with NASH might potentially progress to cirrhosis and treatment is necessary. Patients with NASH have increased risk of death from liver-related and cardiovascular causes [12] .
Diet and lifestyle modification / exercise
NAFLD and NASH are strongly associated with the metabolic syndrome and the majority of patients are overweight or obese, with co-morbidities like diabetes mellitus or insulin resistance and hyperlipidemia. Hence the cornerstone of treatment is a combination of weight reduction and exercise through a combination of diet, physical activity and general lifestyle changes [13] . Behavioural change through diet and exercise may not suffice alone as other parameters are still under investigation, such as smoking, which is associated with increased insulin resistance and possibly with advanced liver fibrosis [14, 15] .
From as early as 1970, studies indicated that weight loss is associated with improvement in liver histology as evidenced by follow up biopsies [16] and liver enzyme levels [17] . Small studies verified that weight reduction is correlated with lower levels of aminotransferases and showed that liver biochemistry was aggravated when patients regained weight [18] . The prevalence of metabolic syndrome in obese patients was also reduced when weight loss was achieved by diet and medical treatment [19] . Patients who accomplish a reduction of more than 5% of their body weight have improved insulin sensitivity and steatosis. Furthermore, when patients A randomized controlled trial (RCT) with 31 patients tested the efficacy of intense dietary and lifestyle interventions with exercise compared with general education for 48 weeks. The lifestyle interventions arm achieved an average of 9.3% reduction of body weight versus 0.2% in the other group, which was also associated with a beneficial effect in liver histology since liver steatosis was improved. Overall a weight loss of more than 7% of body weight was linked to significant improvement in steatosis, lobular inflammation, ballooning and NAS, but not fibrosis. Whether liver fibrosis may not be affected as much from weight loss or whether a longer treatment period is needed, is unclear [11] . However a recent retrospective study of 45 patients showed regression of fibrosis when patients lost more than 10% of body weight regardless of the method used (bariatric therapy, diet, medical therapy for weight loss). In addition when patients regained weight, fibrosis worsened [21] .
The largest clinical study thus far, assessed 293 individuals with biopsy proven NASH for one year. Patients received dietary advice, motivation to exercise and were instructed to log their daily caloric consumption and activities. Assessment of follow up biopsies recorded a 25% resolution of NASH and a 47% of NAS improvement. Improvement in portal inflammation and fibrosis was greater in patients with weight loss more than 10% of body weight. In total 19% of patients achieved regression of fibrosis after a year. It is noteworthy that from those patients who reached 10% of weight loss, 45% showed regression of fibrosis thus underlining the importance of weight reduction as well as the dose-response relationship between weight loss and hepatic histology improvement. On the other hand the majority of patients with deteriorating liver histology had minimal or no weight loss. In total, less F o r P e e r R e v i e w O n l y than 50% of patients lost more than 7% of body weight and 25% achieved resolution of NASH questioning the efficacy of these interventions in real life where usually success rates are lower [22] .
Published studies highlight the association between diet and exercise with improvement in the biochemical levels and histological findings of NAFLD patients [23] . Further supporting the role of dietary intervention, small studies displayed histological improvement though without statistical significance [24] . The focus of current research is to characterize unhealthy dietary habits for NAFLD patients. In this setting, a prospective study showed that NAFLD patients tend to consume more soft drinks and meat and less omega-3 fatty acids [25] . Similarly fructose consumption is increased in NAFLD patients and is associated with increased fibrosis [26] . Interestingly, diets with either restriction of fat or carbohydrate result in weight reduction [27] while the Mediterranean diet seems to improve liver steatosis and insulin sensitivity even without weight loss, albeit in a small group of patients [28] .
Exercise, along with diet, is a key part of behavioral changes with both beneficial effects in cardiovascular risk factors and leading to body weight reduction [29] . Despite the fact that physical activity plays an important role in NAFLD management, the majority of patients do not exercise and fitness is inversely associated with the prevalence of NAFLD [30] . Indeed even when weight loss is not accomplished through exercise there are beneficial results from physical activity. A placebo controlled RCT of 19 sedentary obese patients assessed hepatic function by magnetic resonance imaging and blood testing after 4 weeks of aerobic training or placebo (stretching), documenting a reduction in hepatic triglyceride concentration [31] . In a similar study, resistance exercise decreased fat concentration in the liver, as Data from a recent meta-analysis suggests that exercise has a beneficial role in reducing intrahepatic lipids but not in the improvement of liver biochemistry even when weight reduction is minimal or none. The vast heterogeneity and small number of studies included in the analyses indicates that more research regarding exercise interventions is required in order to accurately assess its role in NAFLD treatment [33] . Furthermore the same researchers concluded that changes in the intensity or amount of aerobic exercise do not have a significant effect on liver fat reduction and fail to improve weight loss [34] . Despite this finding, a significant difference between all exercise groups and placebo was documented in regards to intrahepatic lipid and visceral adipose tissue, as measured by magnetic resonance [34].
Orlistat
Weight reduction through diet and lifestyle modification is advocated as the first line of intervention in NASH but the majority of real life patients are unable to comply with dietary modifications. Orlistat, an oral inhibitor of gastric and pancreatic lipases, was introduced in obese patients with NASH in order to assist with weight loss. Initially a case series of 3 patients showed marked improvement in histological and biochemical markers after 6 or 12 months of orlistat treatment [35] . In a RCT of 52 patients, orlistat in conjunction with a weight loss program reduced ALT levels and steatosis by ultrasound after 6 months. Interestingly, there was no significant difference in weight reduction between orlistat and placebo group [36] . Another RCT with fifty overweight patients demonstrated that the reduction of aminotransferases and body weight were similar when comparing treatment with vitamin E plus diet or 
Bariatric surgery
Bariatric surgery is indicated in severely or morbidly obese patients and a variety of procedures have been performed. These procedures include bilio-intestinal bypass, gastric band, laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass and sleeve gastrectomy. Jejuno-ileal bypass was abandoned because of liver complications that developed after surgery ranging from increased fatty infiltration to cirrhosis and liver failure [37] In a small study, laparoscopic adjustable gastric band placement was associated with sustained weigh loss and improved liver biochemistry and insulin sensitivity. Follow up biopsies indicated that steatosis, inflammation, ballooning and fibrosis also reduced, although a lot of patients had to undergo revision surgery [40] .
A prospective study from France evaluated the presence of fibrosis and non-alcoholic steatohepatitis in 381 obese patients after bariatric surgery. They concluded that the majority of patients had decreased steatosis and ballooning after one and five years, albeit inflammation remained unchanged compared with baseline measurements. The 
Insulin sensitizing agents
There is a well-documented association between non-alcoholic steatohepatitis and the metabolic syndrome. This association has led to a rigorous investigation of the majority of type 2 diabetes regimens for the treatment of NAFLD and NASH. 
Metformin

Thiazolidinediones
Pioglitazone and rosiglitazone are agonists of the nuclear peroxisome proliferator activated receptor-gamma (PPARγ), thus acting by improving insulin sensitivity. The effect of rosiglitazone and pioglitazone on liver biochemistry and histology (steatosis, ballooning, inflammation and fibrosis) has been vigorously investigated in NASH both in diabetic and non-diabetic patients. Moreover, rosiglitazone has been associated with an increased risk of myocardial infarction and heart failure and as a result is no more accessible in Europe [51, 52] .
In a pilot study of 18 non-diabetic patients with NASH treated with pioglitazone for 48 weeks, liver biochemistry and histology significantly improved [53] . This improvement may be modulated by an adiponectin-mediated effect on insulin sensitivity and hepatic fatty acid metabolism rather than by changes in proinflammatory cytokines [54] . In a RCT of pioglitazone and dietary restriction versus diet restriction alone in 55 patients with NASH, pioglitazone significantly improved all histological measures apart from fibrosis [55] . Interestingly discontinuation of pioglitazone treatment reverses the beneficial effects on aminotransferase levels and inflammation markers [54] . In a UK RCT of 74 patients, pioglitazone treatment for 12 months resulted in significant weight gain and improvements in metabolic and histological parameter, including liver fibrosis [56] . Pioglitazone was associated with significant reductions in hepatic steatosis, lobular inflammation and resolution of steatohepatitis as compared with placebo although no improvement in fibrosis was seen. The study concluded that there was no benefit of pioglitazone over placebo since the drug failed to meet the pre-specified level of significance for the improvement in histologic findings [57] .
There are adverse effects of pioglitazone that need to be acknowledged.
Congestive heart failure increases with pioglitazone, nevertheless without an associated increase in cardiovascular mortality [58, 59] . Furthermore, pioglitazone presents the same side effect profile with the other thiazolidinediones regarding weight gain, bone loss and pedal edema [60] .
Pioglitazone is included in the AASLD and EASL management recommendations for patients with biopsy proven NASH although the optimal duration of treatment is yet to be determined [2, 3] . However the long-term efficacy is debatable and the experience with rosiglitazone suggests no additional benefit with longer therapy schemes [50] . Moreover both biochemical and histological improvement return to baseline after treatment discontinuation while weight gain is not easily reversible [54] .
Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue with longer duration and was introduced for the treatment of diabetes mellitus in obese patients in 
Sitagliptin
Sitagliptin, a dipeptidyl peptidase 4 (DDP-4 inhibitor) is another anti hyperglycemic agent studied in animal models with hopeful results [64] . An open label observational pilot study with 15 NASH patients with diabetes assessed the effect of sitagliptin for one year. Paired liver biopsies revealed a significant decrease in ballooning and histological activity scores [65] . However, when further trials evaluated sitagliptin on patients with NASH, one study was terminated early (NCT01260246) and another was withdrawn prior to enrollment (NCT02263677). In a recent RCT of sitagliptin for 24 weeks in 50 NAFLD patients, there was no significant reduction in liver fat as measured by MRI in comparison with the placebo group [66]. 
Ursodeoxycholic acid (UDCA)
UDCA, a bile acid, was thought to be a promising treatment for NASH based on small pilot studies with the potential to improve liver biochemistry and histology.
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Vitamin E
The hypothesis that an antioxidant agent such as vitamin E (a-tocopherol) can ameliorate liver histology has been frequently tested in NASH patients. Vitamin E improved histological findings in a small double-blind RCT of 49 patients and a prospective open label study of 23 patients after 6 and 12 months of treatment respectively [79, 80] . In those studies the number of patients was small and the dosage and formulation of vitamin E was variable. A combination with pioglitazone was initially tested in a small randomized prospective trial with 20 NASH patients with positive results [81] . Lately the PIVENS and TONIC studies assessed the efficacy of vitamin E in large numbers of patients with biopsy confirmed NASH in adult and paediatric populations respectively. The PIVENS study compared pioglitazone with vitamin E and placebo for 96 weeks and demonstrated the superiority of vitamin E over placebo in the improvement of liver histology [57] . When compared to placebo, vitamin E treatment demonstrated a higher percentage of NAS score improvement (43% vs. 19%) and liver biochemistry improvement [57] . In the children and adolescents cohort, although vitamin E was not superior to placebo in ALT reduction, it resulted in significantly higher resolution of NASH [46] . Both PIVENS and TONIC used 800IU/day of vitamin E for duration of 96 weeks but neither presented sufficient evidence of regression of fibrosis. When vitamin E was used as the control treatment in a study that combined metformin and bicyclol, the histological features of steatosis, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Obeticholic acid (6α-ethyl-chenodeoxycholic acid)
A very promising agent that has emerged from animal and human studies is obeticholic acid, a bile acid derivative that acts as an agonist of the farnesoid X receptor (FXR). Bile acids might interfere in the metabolic pathways of glucose and lipids through the FXR [86] . In a small RCT of 64 diabetic patients with NASH, obeticholic acid administered for 6 weeks increased insulin sensitivity and reduced liver biochemical markers compared to placebo in the expense of a rise in LDL levels [87] . A large, multicentre RCT of obeticholic acid versus placebo for 72 weeks was subsequently performed in 283 patients with biopsy proven NASH [88] . The obeticholic acid group showed improved liver histology compared with placebo, including fibrosis, ballooning, steatosis and inflammation. Furthermore obeticholic acid was associated with weight loss. The most common adverse event were the presence of pruritus, elevated LDL and reduced HDL cholesterol levels in the obeticholic acid group that reversed after treatment [88] . Albeit the presence of pruritus and the rise of total and LDL cholesterol, obeticholic acid appears to be a promising agent for the treatment of NASH, once long term safety is assured and is currently tested in a phase III trial (NCT02548351).
Elafibranor
Elafibranor (formerly known as GFT505) is a dual peroxisome proliferatoractivated receptor alpha/delta agonist (PPARα/δ agonist), which provided some hopeful results in patients with metabolic syndrome and obesity [89, 90] . Human liver PPARα gene expression negatively correlates with NASH severity, while histological 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . In animal models of NAFLD/NASH, elafibranor improved liver histology by both PPAR-a dependent and -independent mechanisms [92] . Subsequently elafibranor was introduced in a double blind placebo controlled RCT with 276 noncirrhotic NASH patients in two doses of 80mg and 120mg daily for 52 weeks in order to define histological response. The primary outcome of reversal of NASH without worsening of fibrosis was not achieved in the elafibranor arms compared with placebo. Nevertheless, when a post hoc analysis assessed the response using a modified definition of NASH resolution, the 120mg arm exhibited a significant improvement. Furthermore liver biochemistry, glucose and lipids profiles were reduced as well, without weight gain [93] . An ongoing phase III trial will further evaluate the efficacy and long term safety of elafibranor versus placebo in NASH patients (NCT02704403).
The future
Future research for effective pharmacotherapy treatment in NAFLD and NASH is challenging. A lot of agents are being investigated and some emerging data from rodent trials are promising. As NASH pathogenesis and progression are illuminated, more potential therapeutic targets emerge [94] . Novel drugs aim at multiple targets and pathways, such as inflammation and oxidative stress, the gut liver axis, the metabolic factor and progression of fibrosis [95] .
Aramchol, a fatty acid-bile conjugate is a potential therapeutic agent which seems to reduce liver fat as assessed by magnetic resonance spectroscopy [96] . An ongoing trial is recruiting patients to evaluate the efficacy and safety of two aramchol doses versus placebo in NASH patients (NCT02279524). Volixibat (SHP-626), is an 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 An inhibitor of phosphodiesterase-4 (ASP9831) with promising results from a phase 1 trial was evaluated in 93 patients with NASH compared with placebo but no significant change was observed in liver biochemistry after 12 weeks of administration at either of the two investigated doses [100] . In murine models of NASH, a pan-caspase inhibitor, emricasan (IDN-6556) reduced hepatocyte apoptosis and consequently attenuated liver injury and fibrosis [101] . Emricasan significantly reduced transaminases after 28 days in 38 patients with NAFLD [102] . A larger RCT is currently recruiting participants (NCT02686762).
Cenicriviroc, a dual CCR2/CCR5 antagonist is evaluated in a phase 2b randomized, double blind, placebo controlled study with 289 NASH patients for a period of 2 years [103] .
GS-6624 (simtuzumab) is a monoclonal antibody against lysyl oxidase-like 2 (LOXL2) and GS-4497 is a molecule that inhibits apoptosis signal-regulating kinase 1 (ASK1) which acts as a mediator of oxidative stress. Both these agents are being 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 antibodies that reduce insulin resistance in animals were included in small trial designs for NASH patients and leaded to positive results demanding further research in the immediate future [104] .
Conclusions
There is a documented global increase of NAFLD and NASH related to the epidemic of the metabolic syndrome and obesity leading to increasing morbidity, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to demonstrate that the improvement in these surrogate end-points translates into a clinical meaningful benefit to patients [105] . The presence or severity of NASH has not been associated with clinical outcomes in long-term cohort studies [106] , whereas only the presence of advanced fibrosis was associated with liver-related events [107] .
Moreover, there is significant intra-and inter-observer variability in the assessment of the NAS score, which has so far jeopardized the outcome of well-conducted RCTs [57, 93] . Therefore, the resolution of NASH endpoint (or any decrease of the NAS score) is of questionable utility. We propose the exploration of quantitative fibrosis assessment using the collagen proportionate area as a surrogate endpoint, that would allow for the detection of finer changes in fibrosis and could potentially shorten the duration of clinical trials [108, 109, 110] . CPA assessment would probably require a modified method to capture and measure the finer pericellular fibrosis which is present in NASH.
Moreover, the identification of clinically relevant biomarkers of disease regression that could potentially alleviate the need for serial biopsies and would increase study recruitment is an unmet need. A current innovative medicines initiative call, which represents a collaboration between the European Commission and the European pharmaceutical industry, will hopefully address this issue. Since NASH has multiple potential pathways of development, combination treatment will also be explored at some point in the future. Ultimately, if there are no large scale interventions from a public health policy perspective to actively implement changes in lifestyle, the toll of morbidity and mortality will continue to rise irrespective of any small scale success in pharmaceutical therapy.
Five-year view
At the moment, there are promising agents in large scale phase III trials (obeticholic acid, elafibranor) and others in phase II trials (cenicriviroc, simtuzumbab, volixibat) that target different pathways of NASH development and progression. As NASH is classified as a medical condition of an unmet therapeutic need, it has gained an accelerated access pathway for drug approval based on surrogate endpoints. It is therefore expected that within the next five years, there will be at least one approved agent for the pharmacological treatment of pre-cirrhotic NASH. It is also expected that biomarker research will have identified candidate markers that will allow better characterization of patients and reduce the need for a liver biopsy.
Key issues
* NAFLD has become the most common cause for chronic liver disease in the developed world. * Dietary and lifestyle interventions provide beneficial results but are difficult to maintain in the long term. * Although there is no universally approved medical treatment, both the EASL and AASLD guidelines suggest pioglitazone and vitamin E use in selected cases. * As NASH is classified as a medical condition of an unmet therapeutic need, it has gained an accelerated access pathway for drug approval based on surrogate endpoints. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
